Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctioninterleukin-8 receptor activity

CXCR1 CXCR2

1.71e-052832GO:0004918
GeneOntologyMolecularFunctioninterleukin-8 binding

CXCR1 CXCR2

5.11e-053832GO:0019959
GeneOntologyMolecularFunctionlysine-acetylated histone binding

BRD2 BRD4 BRD3

2.59e-0430833GO:0070577
GeneOntologyMolecularFunctionacetylation-dependent protein binding

BRD2 BRD4 BRD3

2.86e-0431833GO:0140033
GeneOntologyMolecularFunctionC-X-C chemokine binding

CXCR1 CXCR2

3.54e-047832GO:0019958
GeneOntologyMolecularFunctionC-X-C chemokine receptor activity

CXCR1 CXCR2

4.70e-048832GO:0016494
GeneOntologyMolecularFunctionphosphotransferase activity, alcohol group as acceptor

STK10 BRD2 PIK3C2A BRD4 MARK4 PGM2L1 IRAK3 DGKD LTBP1 PFKFB3

7.02e-047098310GO:0016773
GeneOntologyBiologicalProcessinterleukin-8-mediated signaling pathway

CXCR1 CXCR2

1.56e-052822GO:0038112
GeneOntologyBiologicalProcesscellular response to interleukin-8

CXCR1 CXCR2

4.67e-053822GO:0098759
GeneOntologyBiologicalProcessresponse to interleukin-8

CXCR1 CXCR2

4.67e-053822GO:0098758
DomainBET

BRD2 BRD4 BRD3

3.02e-074803PF17035
DomainNET_dom

BRD2 BRD4 BRD3

3.02e-074803IPR027353
DomainNET

BRD2 BRD4 BRD3

3.02e-074803PS51525
DomainBromodomain_CS

BPTF BRD2 BRD4 BRD3

4.34e-0626804IPR018359
DomainChemokine_CXCR_1/2

CXCR1 CXCR2

1.81e-052802IPR000174
DomainBROMODOMAIN_1

BPTF BRD2 BRD4 BRD3

1.85e-0537804PS00633
DomainBromodomain

BPTF BRD2 BRD4 BRD3

2.06e-0538804PF00439
DomainBROMODOMAIN_2

BPTF BRD2 BRD4 BRD3

2.80e-0541804PS50014
DomainBROMO

BPTF BRD2 BRD4 BRD3

3.09e-0542804SM00297
DomainBromodomain

BPTF BRD2 BRD4 BRD3

3.09e-0542804IPR001487
Domain-

BPTF BRD2 BRD4 BRD3

3.09e-05428041.20.920.10
DomainNuc_orph_rcpt

NR4A2 NR4A3

5.42e-053802IPR003070
DomainCXCR4/ACKR2

CXCR1 CXCR2

3.75e-047802IPR001277
Domainzf-C4

NR4A2 NR4A3 NR1H4

1.01e-0346803PF00105
DomainZnf_hrmn_rcpt

NR4A2 NR4A3 NR1H4

1.01e-0346803IPR001628
DomainNuclear_hrmn_rcpt

NR4A2 NR4A3 NR1H4

1.01e-0346803IPR001723
DomainNUCLEAR_REC_DBD_2

NR4A2 NR4A3 NR1H4

1.01e-0346803PS51030
DomainNUCLEAR_REC_DBD_1

NR4A2 NR4A3 NR1H4

1.01e-0346803PS00031
DomainZnF_C4

NR4A2 NR4A3 NR1H4

1.01e-0346803SM00399
Domain-

NR4A2 NR4A3 NR1H4

1.07e-03478031.10.565.10
DomainHOLI

NR4A2 NR4A3 NR1H4

1.14e-0348803SM00430
DomainNucl_hrmn_rcpt_lig-bd

NR4A2 NR4A3 NR1H4

1.14e-0348803IPR000536
DomainHormone_recep

NR4A2 NR4A3 NR1H4

1.14e-0348803PF00104
DomainCysPc

ADGB CAPN5

1.83e-0315802SM00230
DomainPeptidase_C2_calpain_cat

ADGB CAPN5

1.83e-0315802IPR001300
DomainPeptidase_C2

ADGB CAPN5

1.83e-0315802PF00648
DomainCALPAIN_CAT

ADGB CAPN5

1.83e-0315802PS50203
Domain-

NR4A2 NR4A3 NR1H4

1.87e-03578033.30.50.10
DomainZnf_NHR/GATA

NR4A2 NR4A3 NR1H4

1.97e-0358803IPR013088
Pubmed

Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.

BRD2 BRD4 BRD3

1.36e-08384331792058
Pubmed

Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration.

BRD2 BRD4 BRD3

1.36e-08384324049186
Pubmed

BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.

BRD2 BRD4 BRD3

1.36e-08384329437854
Pubmed

Expression of BET genes in testis of men with different spermatogenic impairments.

BRD2 BRD4 BRD3

5.43e-08484322035730
Pubmed

Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins.

BRD2 BRD4 BRD3

5.43e-08484324248598
Pubmed

Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.

BRD2 BRD4 BRD3

5.43e-08484322912406
Pubmed

Intron 1-Mediated Regulation of EGFR Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins.

BRD2 BRD4 BRD3

2.70e-07684331444232
Pubmed

BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail.

BRD2 BRD4 BRD3

7.54e-07884331311807
Pubmed

Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.

BPTF BRD2 BRD4 BRD3 DNAH9

1.10e-067584525593309
Pubmed

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

BRD2 BRD4 BRD3

2.21e-061184328805820
Pubmed

Effects of CXCR1 and CXCR2 inhibition on expansion and differentiation of umbilical cord blood CD133(+) cells into megakaryocyte progenitor cells.

CXCR1 CXCR2

5.76e-06284221555225
Pubmed

Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.

CXCR1 CXCR2

5.76e-06284219585580
Pubmed

CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury.

CXCR1 CXCR2

5.76e-06284221254176
Pubmed

Transcriptional Profiling of Monocytes Deficient in Nuclear Orphan Receptors NR4A2 and NR4A3 Reveals Distinct Signalling Roles Related to Antigen Presentation and Viral Response.

NR4A2 NR4A3

5.76e-06284234248958
Pubmed

Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor.

CXCR1 CXCR2

5.76e-06284230218547
Pubmed

Collagen-Derived N-Acetylated Proline-Glycine-Proline in Intervertebral Discs Modulates CXCR1/2 Expression and Activation in Cartilage Endplate Stem Cells to Induce Migration and Differentiation Toward a Pro-Inflammatory Phenotype.

CXCR1 CXCR2

5.76e-06284226302999
Pubmed

Elevated expression of the interleukin-8 receptors CXCR1 and CXCR2 in peripheral blood cells in obstructive coronary artery disease.

CXCR1 CXCR2

5.76e-06284221915051
Pubmed

The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature.

CXCR1 CXCR2

5.76e-06284218668539
Pubmed

Expression of CXCR-1 and CXCR-2 chemokine receptors on synovial neutrophils in inflammatory arthritides: does persistent or increasing expression of CXCR-2 contribute to the chronic inflammation or erosive changes?

CXCR1 CXCR2

5.76e-06284216987681
Pubmed

Bronchoepithelial expression of CXCR1 and CXCR2 does not facilitate transepithelial migration of neutrophils.

CXCR1 CXCR2

5.76e-06284222076427
Pubmed

Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases.

CXCR1 CXCR2

5.76e-06284212442335
Pubmed

Roles of mechanical force and CXCR1/CXCR2 in shear-stress-induced endothelial cell migration.

CXCR1 CXCR2

5.76e-06284221989491
Pubmed

Mouse mutants in schizophrenia risk genes GRIN2A and AKAP11 show EEG abnormalities in common with schizophrenia patients.

AKAP11 GRIN2A

5.76e-06284236914641
Pubmed

Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.

CXCR1 CXCR2

5.76e-06284230341468
Pubmed

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation.

BRD2 BRD4

5.76e-06284232151278
Pubmed

Comparison of the genomic organization and promoter function for human interleukin-8 receptors A and B.

CXCR1 CXCR2

5.76e-0628427929358
Pubmed

A minority of cases of acinic cell carcinoma of the salivary glands are driven by an NR4A2 rearrangement: the diagnostic utility of the assessment of NR4A2 and NR4A3 alterations in salivary gland tumors.

NR4A2 NR4A3

5.76e-06284236469101
Pubmed

CXCR1 and CXCR2 are novel mechano-sensors mediating laminar shear stress-induced endothelial cell migration.

CXCR1 CXCR2

5.76e-06284221036625
Pubmed

BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.

BRD2 BRD4

5.76e-06284223255218
Pubmed

[Effects of Xiaotan Sanjie Decoction on expressions of interleukin-8 and its receptors in gastric tumor xenografts and gastric tissue adjacent to the tumor in mice].

CXCR1 CXCR2

5.76e-06284220082763
Pubmed

The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist.

CXCR1 CXCR2

5.76e-06284220044480
Pubmed

CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival.

CXCR1 CXCR2

5.76e-06284226791948
Pubmed

A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins.

BRD2 BRD4

5.76e-06284224146614
Pubmed

Interleukin-8 in the human fallopian tube.

CXCR1 CXCR2

5.76e-06284211397869
Pubmed

Expression of interleukin-8 receptors in endometriosis.

CXCR1 CXCR2

5.76e-06284215618253
Pubmed

Intracellular cross-talk between the GPCR CXCR1 and CXCR2: role of carboxyl terminus phosphorylation sites.

CXCR1 CXCR2

5.76e-06284217996233
Pubmed

Orphan Nuclear Receptor Family 4A (NR4A) Members NR4A2 and NR4A3 Selectively Modulate Elements of the Monocyte Response to Buffered Hypercapnia.

NR4A2 NR4A3

5.76e-06284238474099
Pubmed

Chromosomal localization, gene structure and transcription pattern of the ORFX gene, a homologue of the MHC-linked RING3 gene.

BRD2 BRD3

5.76e-0628429373153
Pubmed

On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2.

CXCR1 CXCR2

5.76e-06284215028716
Pubmed

Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction.

NR1H4 PLIN2

5.76e-06284224875360
Pubmed

The alteration of RhoA geranylgeranylation and Ras farnesylation breaks the integrity of the blood-testis barrier and results in hypospermatogenesis.

PLEKHA5 GGPS1

5.76e-06284231171774
Pubmed

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.

BRD4 BRD3

5.76e-06284228733670
Pubmed

BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis.

BRD2 BRD4

5.76e-06284223115324
Pubmed

CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.

CXCR1 CXCR2

5.76e-06284219401689
Pubmed

Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.

BRD2 BRD4

5.76e-06284226324948
Pubmed

Association of interleukin-8 receptor alpha polymorphisms with chronic obstructive pulmonary disease and asthma.

CXCR1 CXCR2

5.76e-06284215772681
Pubmed

The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription.

BRD2 BRD3

5.76e-06284218406326
Pubmed

A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients.

CXCR1 CXCR2

5.76e-06284217360650
Pubmed

Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east India.

CXCR1 CXCR2

5.76e-06284222171941
Pubmed

Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure.

CXCR1 CXCR2

5.76e-06284227974825
Pubmed

Association between interleukin 8-receptor gene (CXCR1 and CXCR2) polymorphisms and urinary tract infection: Evidence from 4097 subjects.

CXCR1 CXCR2

5.76e-06284229577511
Pubmed

Molecular characterization of receptors for human interleukin-8, GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-2.

CXCR1 CXCR2

5.76e-0628428384312
Pubmed

Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro.

CXCR1 CXCR2

5.76e-06284225022956
Pubmed

Expression of both types of human interleukin-8 receptors on mature neutrophils, monocytes, and natural killer cells.

CXCR1 CXCR2

5.76e-0628427829970
Pubmed

CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.

CXCR1 CXCR2

5.76e-06284226087179
Pubmed

Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2.

BRD2 BRD4

5.76e-06284235839775
Pubmed

Decreased CXCR1 and CXCR2 expression on neutrophils in anti-neutrophil cytoplasmic autoantibody-associated vasculitides potentially increases neutrophil adhesion and impairs migration.

CXCR1 CXCR2

5.76e-06284222152684
Pubmed

[Diagnostic efficiency of determining CXCR1, CXCR2 and hyaluronic acid blood level in non-small cell lung cancer patients].

CXCR1 CXCR2

5.76e-06284234730557
Pubmed

Lack of Association of Polymorphism Located Upstream of ABCA1 (rs2472493), in FNDC3B (rs7636836), and Near ANKRD55-MAP3K1 Genes (rs61275591) in Primary Open-Angle Glaucoma Patients of Saudi Origin.

FNDC3B ABCA1

5.76e-06284236980976
Pubmed

Phagocytosing neutrophils down-regulate the expression of chemokine receptors CXCR1 and CXCR2.

CXCR1 CXCR2

5.76e-06284212239185
Pubmed

Regulation of CXCR/IL-8 in human airway epithelial cells.

CXCR1 CXCR2

5.76e-06284220016196
Pubmed

Expression of CXC receptor 1 and 2 in esophageal mucosa of patients with reflux esophagitis.

CXCR1 CXCR2

5.76e-06284215793866
Pubmed

Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2.

CXCR1 CXCR2

5.76e-06284215265017
Pubmed

Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification.

BRD2 BRD4

5.76e-06284228588073
Pubmed

CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease.

CXCR1 CXCR2

5.76e-06284222088968
Pubmed

Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.

CXCR1 CXCR2

5.76e-06284226847910
Pubmed

Recruitment of Brd3 and Brd4 to acetylated chromatin is essential for proinflammatory cytokine-induced matrix-degrading enzyme expression.

BRD4 BRD3

5.76e-06284230786900
Pubmed

Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes.

BRD2 BRD4

5.76e-06284216940503
Pubmed

BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.

BRD4 BRD3

5.76e-06284229240787
Pubmed

Nuclear NR4A2 (Nurr1) Immunostaining is a Novel Marker for Acinic Cell Carcinoma of the Salivary Glands Lacking the Classic NR4A3 (NOR-1) Upregulation.

NR4A2 NR4A3

5.76e-06284232341238
Pubmed

WHAT do viruses BET on?

BRD2 BRD4

5.76e-06284220036832
Pubmed

SARS-CoV-2 E protein interacts with BRD2 and BRD4 SEED domains and alters transcription in a different way than BET inhibition.

BRD2 BRD4

5.76e-06284239066826
Pubmed

Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype.

CXCR1 CXCR2

5.76e-06284214713106
Pubmed

Chemokine Receptors, CXCR1 and CXCR2, Differentially Regulate Exosome Release in Hepatocytes.

CXCR1 CXCR2

5.76e-06284227551720
Pubmed

Altered protein prenylation in Sertoli cells is associated with adult infertility resulting from childhood mumps infection.

PLEKHA5 GGPS1

5.76e-06284223825187
Pubmed

[The role of CXCR1/2 in shear stress-induced endothelial cell migration].

CXCR1 CXCR2

5.76e-06284219634663
Pubmed

NR4A orphan nuclear receptor family members, NR4A2 and NR4A3, regulate neutrophil number and survival.

NR4A2 NR4A3

5.76e-06284228637666
Pubmed

Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.

CXCR1 CXCR2

1.73e-05384217295203
Pubmed

Nuclear receptors of the NR4a family are not required for the development and function of follicular T helper cells.

NR4A2 NR4A3

1.73e-05384225899083
Pubmed

CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.

CXCR1 CXCR2

1.73e-05384222996693
Pubmed

NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors.

NR4A2 NR4A3

1.73e-05384222996661
Pubmed

Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients.

NR4A2 NR4A3

1.73e-05384227159982
Pubmed

Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells.

CXCR1 CXCR2

1.73e-0538429843397
Pubmed

Inhibition of adipocyte differentiation by Nur77, Nurr1, and Nor1.

NR4A2 NR4A3

1.73e-05384218945812
Pubmed

CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation.

CXCR1 CXCR2

1.73e-05384221749879
Pubmed

The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.

NR4A2 NR4A3

1.73e-05384222143616
Pubmed

Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3.

CXCR1 CXCR2

1.73e-05384211196695
Pubmed

Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses.

NR4A2 NR4A3

1.73e-05384216873729
Pubmed

Structure and functional expression of a human interleukin-8 receptor.

CXCR1 CXCR2

1.73e-0538421840701
Pubmed

The orphan nuclear receptor Nur77 is a determinant of myofiber size and muscle mass in mice.

NR4A2 NR4A3

1.73e-05384225605333
Pubmed

CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization.

CXCR1 CXCR2

1.73e-05384217204468
Pubmed

Molecular evolution of the human interleukin-8 receptor gene cluster.

CXCR1 CXCR2

1.73e-0538421303245
Pubmed

Association of single nucleotide polymorphisms in CXCR1, CXCR2 and CXCL5 with Behçet disease: a study in the Denizli province of Turkey.

CXCR1 CXCR2

1.73e-05384234050991
Pubmed

Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors.

CXCR1 CXCR2

1.73e-05384220630874
Pubmed

Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers.

CXCR1 CXCR2

1.73e-05384219890050
Pubmed

Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial.

CXCR1 CXCR2

1.73e-05384216679868
Pubmed

The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities.

CXCR1 CXCR2

1.73e-05384215946947
Pubmed

The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma.

CXCR1 CXCR2

1.73e-05384222626766
Pubmed

Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli.

NR4A2 NR4A3

1.73e-05384215964844
Pubmed

Monomer-dimer equilibria of interleukin-8 and neutrophil-activating peptide 2. Evidence for IL-8 binding as a dimer and oligomer to IL-8 receptor B.

CXCR1 CXCR2

1.73e-0538428195702
GeneFamilyCD molecules|C-X-C motif chemokine receptors

CXCR1 CXCR2

1.30e-0465421094
GeneFamilyNuclear hormone receptors

NR4A2 NR4A3 NR1H4

4.21e-044954371
GeneFamilyC2 domain containing|Calpains

ADGB CAPN5

8.97e-0415542975
CoexpressionGSE17721_LPS_VS_GARDIQUIMOD_24H_BMDC_UP

BST2 BRD4 NR4A2 SLFN12 NR4A3 TMEM39A ALCAM

3.34e-06199837M4063
ToppCellBL-critical-LOC-Myeloid|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

FNDC3B ABCA1 IRAK3 PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.84e-09197848932a7fae4979b561688e6222505df0f4e510ab11
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-A|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

CACNA2D4 NR4A2 NR4A3 PFKFB3 LY96 PLIN2 LAPTM5

7.65e-0819184779e7089022063c5f2b2f1b27658c62b741f3a037
ToppCellBL-critical-LOC-Myeloid-Neutrophil|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

FNDC3B ABCA1 IRAK3 PFKFB3 LY96 CXCR1 CXCR2

9.12e-08196847f64d7fed31e418c55fe946744d78c3cbecec9bbf
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FNDC3B NR4A3 IRAK3 RABGEF1 PFKFB3 LY96 PLIN2

1.01e-07199847880ba91ccecc6633f6daba7822d9200548a8632f
ToppCell10x5'v1-week_14-16-Myeloid_macrophage-stroma-stromal_macrophage|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

ABCA1 NR4A2 NR4A3 MS4A14 PFKFB3 LY96 PLIN2

1.05e-07200847af743dfef7e7cfaef1c494999757123f93a213e3
ToppCellBALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Macrophage-macrophage,_alveolar-Macro_c3-EREG|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

STK10 ABCA1 NR4A3 IRAK3 MS4A14 LAPTM5

8.48e-071708469ac1ef57f14418a5dd2aa16861c3df698c28f5ed
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FNDC3B ABCA1 IRAK3 ADCY3 PLIN2 LAPTM5

1.35e-06184846e343dd7777a29048e3f12a939f7f782b8b7b4fea
ToppCellmild-unassigned|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

PTPN13 MARK4 ADCY3 CXCR1 CXCR2 FAM111B

1.43e-061868465b2e1a58916f392fa1156bf9210df528775248ff
ToppCellCOVID-19-kidney-Myeloid|COVID-19 / Disease (COVID-19 only), tissue and cell type

STK10 FNDC3B IRAK3 CXCR1 CXCR2 LAPTM5

1.72e-061928460b9d22a222f1201e375f8e55cace9ef939febae4
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FNDC3B ABCA1 NR4A2 NR4A3 IRAK3 LAPTM5

1.83e-06194846449ce4167d64c170d914e0250f739eabedcf915d
ToppCellSmart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

SHROOM3 OTOGL IRAK3 DNAH9 CXCR1 CXCR2

1.88e-06195846d3755929ebbbf5e3afde44281e9056ddb614a291
ToppCell343B-Myeloid-Monocyte|343B / Donor, Lineage, Cell class and subclass (all cells)

NR4A2 NR4A3 PFKFB3 LY96 PLIN2 LAPTM5

1.88e-06195846169b4952118ca5ded55de928a1cf08721cdac193
ToppCellSmart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

SHROOM3 OTOGL IRAK3 DNAH9 CXCR1 CXCR2

1.88e-0619584619853c654ac64b3ae3bc99841c6cb29c8aaba85c
ToppCellControl-Myeloid-Macrophage|Control / Disease state, Lineage and Cell class

FNDC3B ABCA1 IRAK3 ALCAM PLIN2 LAPTM5

1.94e-06196846e2c2a30fa3ee3034fbde5335be169e880dde622d
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid-Monocytic-Classical_Monocyte|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

FNDC3B IRAK3 PFKFB3 CXCR1 CXCR2 LAPTM5

1.94e-06196846d9b5eaca4089d5337f1175a663418c9c675cdd87
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

STK10 ABCA1 IRAK3 ALCAM PFKFB3 LAPTM5

2.00e-061978468af4a1e35ce9fb4ea3d26ab619599efb7eac43a5
ToppCell10x3'2.3-week_14-16-Myeloid_macrophage-stroma-stromal_macrophage|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

ABCA1 NR4A2 NR4A3 PFKFB3 LY96 PLIN2

2.00e-0619784672775eb6c24cfb956436642ac9cd6e4d5c01ea5f
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid-Monocytic|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

FNDC3B IRAK3 PFKFB3 CXCR1 CXCR2 LAPTM5

2.00e-06197846037f5f26fa66818baa35846aa96336155e8a6f45
ToppCelltumor_Lung-T/NK_cells-CD8+/CD4+_Mixed_Th|T/NK_cells / Location, Cell class and cell subclass

BRD2 GZMK NR4A2 NR4A3 PFKFB3 PLIN2

2.00e-06197846dcce1c3dc5f3e53c368f758eb0fd5afcd86325e7
ToppCellIPF-Myeloid-Macrophage|IPF / Disease state, Lineage and Cell class

FNDC3B ABCA1 IRAK3 ALCAM PLIN2 LAPTM5

2.00e-06197846a2ffb33c7cad6be43cbb8ed9a91338923cc07db4
ToppCell343B-Myeloid-Monocyte-CD16+_Monocyte|343B / Donor, Lineage, Cell class and subclass (all cells)

NR4A2 NR4A3 PFKFB3 LY96 PLIN2 LAPTM5

2.00e-061978468d6551e118cfe308088487c6d5171d986f90fb2f
ToppCellcritical-Myeloid|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

FNDC3B ABCA1 LY96 PLIN2 CXCR2 LAPTM5

2.06e-06198846a5807517f8ca93b77f49f5787fd9036178b8fc2a
ToppCellNS-critical-d_0-4-Myeloid|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

FNDC3B ABCA1 IRAK3 LY96 CXCR2 LAPTM5

2.06e-0619884672d51284d267f102c26f0ae8279ee9e11e69c7e3
ToppCell(11)_FOXN4+-(2)_GFP_FOXI1|(11)_FOXN4+ / shred by cell type by condition

BPTF SHROOM3 PTPN13 BRD4 ALCAM TTC3

2.06e-0619884676d40b8c2f8399725b3a62ee2ae0896559cf91eb
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

FNDC3B IRAK3 PFKFB3 LY96 CXCR2 LAPTM5

2.12e-061998469da8b48ec1c1c105fcbab6ae8f08166e7d5e8a35
ToppCellParenchymal-10x5prime-Immune_Myeloid-Macrophage_other|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

ABCA1 NR4A2 ALCAM LY96 PLIN2 LAPTM5

2.18e-06200846eac46978e2b3d38cf42b44f7b0350d0489d036b3
ToppCellBiopsy_IPF-Immune-Monocytes|Biopsy_IPF / Sample group, Lineage and Cell type

NR4A2 NR4A3 IRAK3 RABGEF1 PFKFB3 LAPTM5

2.18e-0620084680b2b7eecc5dce9d22f9c80562e4aea83bbf0f50
ToppCellmild-unassigned|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

PTPN13 OTOF MARK4 CXCR1 CXCR2 FAM111B

2.18e-06200846ca0a08bf162c954f037a56aa0cbb8b5d7c6ffec0
ToppCellLPS-antiTNF-Endothelial-Mes-Like|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ZNF423 AGPAT1 CAPN5 HORMAD1 FAM111B

1.24e-0515884550df52d64d07178975563abd98ce4fddb9f2f7ef
ToppCellfacs-Liver|facs / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

THRSP BST2 FGB TDO2 LAPTM5

1.24e-05158845ea7db6bd9742153ceb6e444892a6d1df9c7fcc96
ToppCelldroplet-Kidney-nan-18m-Lymphocytic-nan|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GZMK NR4A3 CXCR1 CXCR2 LAPTM5

1.48e-05164845731b9c7d6f6ecfb14d4a8705e0ddac9fb460d9a8
ToppCellLPS-antiTNF-Endothelial-Mes-Like-Alv_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ZNF423 AGPAT1 LY96 HORMAD1 FAM111B

1.57e-0516684594a00edf66d54bc5f7343daea700ca26cf38fd90
ToppCellPCW_05-06-Hematologic_Myeloid-Hem_Myeloid_macrophage-im_macrophage_(16)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung

TDRD15 MS4A14 LY96 HORMAD1 LAPTM5

1.62e-051678450d187e40a5b96b595761f7aea1a0835462d8270f
ToppCelldroplet-Liver|droplet / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BST2 FGB TDO2 PLIN2 LAPTM5

1.86e-05172845cd0e8f48836a16026b47ade06abadf26b53f581f
ToppCell10x5'-GI_small-bowel-Lymphocytic_NK|GI_small-bowel / Manually curated celltypes from each tissue

GZMK FAM169A PLPPR5 CXCR1 CXCR2

1.97e-0517484509b216f07cffd3ea2149ea95ffb5cd7219b3a98c
ToppCell5'-Adult-Appendix-Mesenchymal-fibroblastic-Stromal_1_(CCL11+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ABCA1 PTPN13 PLEKHA5 IRAK3 TDO2

1.97e-05174845f90ca117b729436cf452e2ddcec26ba525c5c13b
ToppCell5'-GW_trimst-2-LymphNode-Hematopoietic-Myeloid-LYVE1+_Macrophage|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ABCA1 NR4A2 LY96 PLIN2 LAPTM5

2.02e-05175845c9dc6aa652ac887470806a950311657c423d9495
ToppCellCOVID-19-kidney-PCT-S3-2|COVID-19 / Disease (COVID-19 only), tissue and cell type

TDRD15 FGB TDO2 NR1H4 PROX1

2.08e-05176845b6497324e3e52f514ce556a3fa0c3011c45dcc7b
ToppCell10x5'v1-week_14-16-Myeloid_macrophage-stroma-monocytoid_macrophage|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NR4A2 NR4A3 MS4A14 LY96 PLIN2

2.14e-05177845945b2d0723a0a35c767604ae607d2c2d53bf0c82
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I-A|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

NR4A2 NR4A3 LY96 PLIN2 LAPTM5

2.26e-051798453d3716078afdb9a89ddfadb3197cd1b52fa770be
ToppCellfacs-Large_Intestine-Distal-24m-Epithelial-enteroendocrine_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADGB PAPPA2 PTPRN2 DNAH9 PROX1

2.44e-05182845398ce074a04f6482470b488f1affae4af7d2ec58
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FNDC3B ABCA1 ADCY3 PLIN2 LAPTM5

2.51e-05183845ff751a97466807bf04b5a0740138c61e298cd1fc
ToppCell5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

MS4A14 TWF2 LY96 PLIN2 LAPTM5

2.51e-0518384502deb595819fb864a934fd0fcaad684f1ca42964
ToppCell3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage-Monocyte-derived_macrophage-Monocyte-derived_macrophage_L.1.2.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

NR4A2 NR4A3 PFKFB3 PLIN2 LAPTM5

2.57e-05184845b45b1fdba13c8ed2a04a4fb3b62d8ad92785c768
ToppCell3'-Child04-06-SmallIntestine-Hematopoietic-Myeloid-Monocytes|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

NR4A2 NR4A3 LY96 CXCR1 CXCR2

2.64e-0518584500a991e63e9ac6de3f48a96e3be6073f90cbb442
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-A|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

NR4A3 PFKFB3 LY96 PLIN2 LAPTM5

2.64e-0518584576fc5bbb71e42c0eb70474efcd3a71a7b2633f24
ToppCellfacs-Trachea-18m-Endothelial-endothelial_cell_of_trachea-tracheal_endothelial_cell-tracheal_endothelial_cell_l54|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ABCA1 SLFN12 TDO2 HORMAD1 PROX1

2.64e-0518584559acaf025353405948dc34ccccf37ec5c08ea903
ToppCell3'-Adult-LargeIntestine-Hematopoietic-T_cells-NK_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

GZMK NR4A2 CXCR1 CXCR2 LAPTM5

2.71e-05186845e083356f72995645f873ca0157d56bea5e942044
ToppCellPND03|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ALCAM ITGB6 PLIN2 CXCR2 LAPTM5

2.78e-05187845b3fcb36d853adfdea7172c5591de06f027e50af3
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PAPPA2 FNDC3B PGM2L1 ALCAM ITGB6

2.93e-05189845aadb7a2de4cbe7f0958651f2739bba430b93f5c1
ToppCellControl|World / Disease state, Lineage and Cell class

STK10 FNDC3B ABCA1 RABGEF1 PLIN2

2.93e-05189845fb8dddd3b901081c6bb9ed6f32dafc5cce5f30be
ToppCell10x_3'_v3-spleen_(10x_3'_v3)|10x_3'_v3 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

BRD2 NR4A2 NR4A3 PFKFB3 CXCR2

2.93e-051898450fe8901e10c619c93b7788792da1706a32102c6e
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PAPPA2 FNDC3B PGM2L1 ALCAM ITGB6

2.93e-051898458977f3295b7df7c7474b3f371de90a82ae4bb50c
ToppCell3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

PTPN13 PGM2L1 CAPN5 ALCAM MUC5AC

3.00e-051908456ea9fa08bd97bedcb21d3654467e7f8dd74c8fd0
ToppCellfacs-Thymus-Flowthrough-24m-Mesenchymal-fibroblast|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PAPPA2 NR4A2 NR4A3 PLPPR5 LTBP1

3.00e-05190845990ac07f4b0a22041daac7502f74fafd6d258cba
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid-Monocytic-Classical_Monocyte-Mono_c1-CD14-CCL3|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

FNDC3B IRAK3 PFKFB3 LY96 LAPTM5

3.00e-05190845212f0d9defcc3174e225cc3d90e7814e238794b6
ToppCellfacs-Thymus-Flowthrough-24m-Mesenchymal-fibroblast|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PAPPA2 NR4A2 NR4A3 PLPPR5 LTBP1

3.00e-05190845fc9bbe5e6e0ec3cfa47bf479d8b09a0fc53169cc
ToppCellfacs-Thymus-Flowthrough-24m-Mesenchymal|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PAPPA2 NR4A2 NR4A3 PLPPR5 LTBP1

3.00e-0519084539ecdf8815e235771132684dfc1aff1917e20965
ToppCellrenal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Macrophage_Dendritic|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA1 MS4A14 ACTN3 LY96 LAPTM5

3.08e-0519184551f5af610983aa73b9f4ece6f27d281ebff89a04
ToppCellhuman_hepatoblastoma-Inflammatory_Monocytes|World / Sample and Cell Type and Tumor Cluster (all cells)

STK10 NR4A3 IRAK3 MS4A14 PFKFB3

3.08e-051918453b59bfc6c106ae8a3fbcd4a74bd128c485724921
ToppCellrenal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Macrophage_Dendritic-M2_Macrophage|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA1 MS4A14 ACTN3 LY96 LAPTM5

3.08e-051918458fd6bdc9d2b1c8d364221d7bc68d03921b668ab5
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid-Monocytic-Classical_Monocyte-Mono_c3-CD14-VCAN|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.08e-0519184547156e5f1d790707f42f6283104a44b33af613e5
ToppCellNS-moderate-d_16-33-Myeloid-Neutrophil|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.16e-05192845545c3990cbe3c04bfd95a0ab7499d2c4af509be1
ToppCellILEUM-non-inflamed-(1)_Cytotoxic_CD8_Trm|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)

GZMK NR4A2 NR4A3 PFKFB3 LAPTM5

3.16e-05192845cc9287803cd979e4b81f0649527f1b3bf54d0b83
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group

STK10 FNDC3B FGB DGKD PITPNB

3.16e-051928458b86db2ebe0199fee0e9800566a619a24bfdeed5
ToppCellAnterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

NTNG1 DGKD LTBP1 GRIN2A PROX1

3.32e-0519484552aebb0b563e2c2058e7f0554ae870e47692b163
ToppCellsaliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic-Neutrophil|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.32e-05194845b04cbd240c59755ef7bdeb17fee3028caef6dedb
ToppCellHippocampus-Neuronal|Hippocampus / BrainAtlas - Mouse McCarroll V32

PTPRN2 FAM169A PGM2L1 AKAP11 TTC3

3.32e-051948458aeb347b3024354c9505f4f0fddf0b843489dc6b
ToppCellBALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Monocytic-Classical_Monocyte|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

ABCA1 IRAK3 LY96 PLIN2 LAPTM5

3.32e-051948454f0fe237b326552dd1b018c58f0a26c365cfa6c5
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid-Monocytic-Classical_Monocyte-Mono_c3-CD14-VCAN|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.32e-051948454eef50c38e6edb2ef2cdcd14eb50805f6cd65bc8
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-D|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FNDC3B CACNA2D4 IRAK3 PLIN2 LAPTM5

3.32e-0519484512e42433a7b7c17c46049ef450223daf2976a59a
ToppCellAnterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

NTNG1 DGKD LTBP1 GRIN2A PROX1

3.32e-05194845bd06e2b8d8c06cddf2e4f58849b86e09013acae1
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.32e-05194845607b5d194ba56efa9b106f10f89368fc103712a0
ToppCellsaliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.32e-05194845744fd4580942183a1058717d0c3ac86483e366ed
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.32e-05194845f5367072b259ae170cf0df3d4d871ab41be29d29
ToppCellsaliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic-Neutrophil-Neu_c1-IL1B|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.32e-05194845d2f6c8900b5c448eede8047ca964e94b19bd6ca5
ToppCellBALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Monocytic|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)

ABCA1 IRAK3 LY96 PLIN2 LAPTM5

3.32e-05194845935ec4554d740935d9d9a59d9d6b5293d1c27d1f
ToppCellGoblet_1|World / shred by cell class for nasal brushing

FNDC3B IRAK3 CAPN5 ALCAM MUC5AC

3.40e-05195845d9e4889a2e7b7c97c07c15b043b77837739462e4
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ABCA1 PFKFB3 ADCY3 PLIN2 LAPTM5

3.40e-05195845042b4f44f90eb23caadeced43699b51e5195ab04
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-M2_Macrophage|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA1 IRAK3 MS4A14 LY96 LAPTM5

3.40e-0519584542bfdff88da1d07828c0ad65d412fb1752f0cee4
ToppCellControl-Myeloid|Control / Disease state, Lineage and Cell class

FNDC3B ABCA1 IRAK3 PLIN2 LAPTM5

3.40e-0519584546ce2e403ca5d757e5ba17349b6c7ce5cde1f195
ToppCellBronchial-NucSeq-Epithelial-Epi_airway_secretory|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

SHROOM3 PTPN13 PTPRN2 CAPN5 MUC5AC

3.40e-05195845e7230a849ea31e6eef9bc6f5468938499450582d
ToppCell343B-Myeloid-Monocyte-CD14+_Monocyte|343B / Donor, Lineage, Cell class and subclass (all cells)

NR4A2 NR4A3 PFKFB3 PLIN2 LAPTM5

3.40e-05195845b5ee368c97113432fc8fe742654cd538558f327c
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PTPRN2 PFKFB3 LY96 CXCR2 LAPTM5

3.48e-05196845fe8d3f45a64323947c36b127355d5940eb56c0ca
ToppCellsaliva-Severe-critical_progression_d28-40-Myeloid|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

IRAK3 PFKFB3 LY96 CXCR2 LAPTM5

3.48e-051968456230b4a26770d30f1ab83345c087f03be1be0f9e
ToppCell368C-Myeloid-Monocyte-CD14+_Monocyte|368C / Donor, Lineage, Cell class and subclass (all cells)

NR4A2 NR4A3 PFKFB3 PLIN2 LAPTM5

3.48e-051968458095b3c1a87ce5c1c7dcbd951806fa564c795068
ToppCellCOVID-19_Convalescent-CD4+_Tcm|COVID-19_Convalescent / Disease condition and Cell class

PTPN13 ADSL GZMK PGM2L1 LY96

3.48e-05196845f2a5eeb1cebde2762865ab29792370b751214c4d
ToppCell368C-Myeloid-Monocyte|368C / Donor, Lineage, Cell class and subclass (all cells)

NR4A2 NR4A3 PFKFB3 PLIN2 LAPTM5

3.48e-051968453b46a501590aa03e3b7e25943dd43b72ecaf8182
ToppCell3'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

NR4A2 NR4A3 IRAK3 PFKFB3 LAPTM5

3.48e-05196845555c9e443fe3b9893cb320b78d84002e1f8c1701
ToppCell367C-Myeloid-Monocyte|367C / Donor, Lineage, Cell class and subclass (all cells)

NR4A2 NR4A3 IRAK3 PFKFB3 PLIN2

3.48e-05196845202066aeb837659fcc2e127fb52d7189e2e3520d
ToppCell10x5'-Lung-Myeloid_Mac-Intermediate_macrophages|Lung / Manually curated celltypes from each tissue

FNDC3B NR4A2 NR4A3 PFKFB3 PLIN2

3.48e-05196845fede2c605f7581ce2ea7a284cffffa1a3970d811
ToppCellmoderate-Myeloid|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.48e-0519684576a4c615ea7594e99c1a938d6900a1b262cc09f5
ToppCellNS-moderate-d_16-33-Myeloid|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

PFKFB3 LY96 CXCR1 CXCR2 LAPTM5

3.48e-05196845dc8483625f1188771eb98bd94757b25163b2fc2f
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PTPRN2 PFKFB3 LY96 CXCR2 LAPTM5

3.48e-05196845526d037bb12d81f1c235c60ddc787fbad0bbad77
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

FNDC3B CACNA2D4 IRAK3 PLIN2 LAPTM5

3.48e-05196845a44a648bf209ce037bfc7b3adfcb220aab60728c
ToppCell3'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

NR4A2 NR4A3 IRAK3 PFKFB3 LAPTM5

3.48e-05196845a1b21f4667c05e837a1229cc5934db805ad562c5
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ABCA1 PFKFB3 LY96 PLIN2 LAPTM5

3.57e-051978456c42ce26574adcc6dfc5dd8109c9943fe5cf12d5
ToppCell343B-Lymphocytic-NK_cells-NK_cell_A|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

BRD2 GZMK NR4A2 NR4A3 PLIN2

3.57e-05197845cd54e6ad175529327fa0372033016b3b978dd452
ToppCell3'-GW_trimst-2-LargeIntestine-Hematopoietic-Myeloid|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ABCA1 NR4A2 NR4A3 LY96 LAPTM5

3.57e-0519784567bf15ee83938bd40f6ecd5abaaf90ad95096d21
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_MHC-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ABCA1 BST2 NR4A2 NR4A3 LAPTM5

3.57e-051978450c8650bde08e1317baee4793201645d86f16e15d
ComputationalGenes upregulated in subsets of cells of a given type within various tumors

FNDC3B BPTF NEB TTC3

1.18e-0449564GAVISH_3CA_MALIGNANT_METAPROGRAM_41_UNASSIGNED
DrugDiethylstilbestrol [56-53-1]; Up 200; 15uM; MCF7; HT_HG-U133A

HTR4 GZMK NR4A2 NR4A3 ALCAM ITGB6 NR1H4

4.49e-061798473895_UP
Druglipopolysaccharide, Escherichia coli O111 B4

ABCA1 BRD2 COPE BRD4 IRAK3 BRD3 LY96

6.20e-06188847ctd:C440499
DrugPicotamide monohydrate [80530-63-8]; Up 200; 10.2uM; MCF7; HT_HG-U133A

BST2 ZNF423 MARK4 GZMK ZFHX2 THAP9 NR1H4

8.14e-061968472233_UP
Drugestradiol; Down 200; 0.01uM; MCF7; HT_HG-U133A

ABCA1 HTR4 ZNF423 SLFN12 NR4A3 ACTN3 CXCR2

8.42e-061978475905_DN
DrugOTX015

BRD2 BRD4 BRD3

2.62e-0516843ctd:C000605331
Drugdiaminocyclobut-3-ene-1,2-dione

CXCR1 CXCR2

4.03e-053842CID002781329
Drug5-methoxysalicylaldehyde

CXCR1 CXCR2

4.03e-053842CID000095695
DrugDTTA

CXCR1 CXCR2

4.03e-053842CID000166909
DrugIonophores

CXCR1 CXCR2

4.03e-053842ctd:D007476
Drugdimethylcyclohexane

CXCR1 CXCR2

4.03e-053842CID000011549
Drug17-AAG; Up 200; 1uM; HL60; HT_HG-U133A

PAPPA2 PTPRN2 BST2 NR4A2 NR4A3 VPS13B

4.99e-051778462678_UP
DrugAC1NBLOD

PTPRN2 CXCR1 CXCR2

5.28e-0520843CID004469991
DrugLuteolin [491-70-3]; Up 200; 14uM; HL60; HT_HG-U133A

PAPPA2 NR4A2 NR4A3 MSH4 NEB ITGB6

7.83e-051928463041_UP
Drugnitroethylene

CXCR1 CXCR2

8.03e-054842CID000077197
Drugdeltorphin II, Ala(2)-

CXCR1 CXCR2

8.03e-054842ctd:C060209
DrugAconitine [302-27-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A

PAPPA2 HTR4 FGB CAPN5 DNAH9 THAP9

8.29e-051948462776_UP
Drug(1)-Nipecotic acid [498-95-3]; Down 200; 31uM; HL60; HT_HG-U133A

PAPPA2 MARK4 NR4A3 IRAK3 LTBP1 ADCY3

8.77e-051968463121_DN
DrugTremorine dihydrochloride [300-68-5]; Up 200; 15uM; MCF7; HT_HG-U133A

ABCA1 ZNF423 ALCAM LY96 NEB MUC5AC

9.02e-051978463196_UP
DrugHydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A

ADGB ZNF423 BRD4 MARK4 NR4A2 VPS13B

9.02e-051978466011_UP
DrugAG-013608 [351320-38-2]; Down 200; 10uM; MCF7; HT_HG-U133A

HTR4 ZNF423 SLFN12 NR4A3 ACTN3 CXCR2

9.28e-051988465904_DN
DrugCarbetapentane citrate [23142-01-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A

PTPRN2 MARK4 FGB ZFHX2 MUC5AC VPS13B

9.28e-051988462623_UP
DrugMethoxamine hydrochloride [61-16-5]; Up 200; 16.2uM; PC3; HT_HG-U133A

PAPPA2 GZMK NR4A2 NTNG1 IRAK3 PROX1

9.28e-051988466627_UP
DrugBisoprolol fumarate; Up 200; 9uM; PC3; HT_HG-U133A

HTR4 NR4A2 NTNG1 ZFHX2 NEB LAPTM5

9.28e-051988466748_UP
DrugCanavanine sulfate monohydrate (L,+) [206996-57-8]; Up 200; 13.6uM; PC3; HT_HG-U133A

HTR4 PTPRN2 NR4A2 LY96 ITGB6 CXCR2

9.54e-051998464197_UP
DrugSTOCK1N-28457; Up 200; 20uM; MCF7; HT_HG-U133A

PAPPA2 ZNF423 NR4A2 CAPN5 NEB MUC5AC

9.54e-051998466869_UP
DrugEtidronic acid, disodium salt [7414-83-7]; Up 200; 16uM; MCF7; HT_HG-U133A

HTR4 NR4A2 NR4A3 ACTN3 MUC5AC CXCR2

9.81e-052008464387_UP
DrugGuanfacine hydrochloride [29110-48-3]; Up 200; 14.2uM; MCF7; HT_HG-U133A

ADGB PAPPA2 BST2 TWF2 ALCAM CXCR2

9.81e-052008465621_UP
DrugFenofibrate

ABCA1 THRSP BRD2 UGT1A6 FGB SMPD4 RABGEF1 TDO2 NR1H4 PLIN2

9.92e-056248410ctd:D011345
Diseaseurate measurement, bone density

PTPRN2 UGT1A6 AGPAT1 MARK4 DGKD PITPNB TDO2 DNAH9 THAP9 ITGB6

9.44e-066198310EFO_0003923, EFO_0004531
Diseaseurate measurement, spine bone mineral density

PAPPA2 UGT1A6 MARK4 LTBP1

2.20e-0558834EFO_0004531, EFO_0007701
Diseasecholelithiasis

SHROOM3 ADSL UGT1A6 VPS13B

1.13e-0488834EFO_0004799
Diseasepremature menopause (biomarker_via_orthology)

ABCA1 NR1H4

2.16e-048832DOID:10787 (biomarker_via_orthology)
DiseaseChildhood Medulloblastoma

BRD2 BRD4 BRD3

2.44e-0443833C0278510
DiseaseMelanotic medulloblastoma

BRD2 BRD4 BRD3

2.44e-0443833C1275668
DiseaseMedullomyoblastoma

BRD2 BRD4 BRD3

2.44e-0443833C0205833
DiseaseDesmoplastic Medulloblastoma

BRD2 BRD4 BRD3

2.44e-0443833C0751291
DiseaseAdult Medulloblastoma

BRD2 BRD4 BRD3

2.44e-0443833C0278876
Diseasepathological myopia

ABCA1 PTPRN2 PLPPR5 DNAH9

2.77e-04111834EFO_0004207
DiseaseX-21448 measurement

UGT1A6 DGKD

3.47e-0410832EFO_0800816
DiseaseMedulloblastoma

BRD2 BRD4 BRD3

3.82e-0450833C0025149
DiseaseBipolar Disorder

HTR4 NR4A2 NTNG1 GRIN2A TDO2 PFKFB3 ADCY3

3.98e-04477837C0005586
Diseasequality of life during menstruation measurement, dysmenorrheic pain measurement

GRIN2A VPS13B

4.23e-0411832EFO_0007889, EFO_0009366
Diseaseneutrophil count, basophil count

HTR4 MARK4 BRD3 CXCR1 CXCR2

4.33e-04224835EFO_0004833, EFO_0005090
Diseasetriglycerides in LDL measurement

TDRD15 BPTF ABCA1

5.34e-0456833EFO_0022320
Diseaselow density lipoprotein particle size measurement

TDRD15 ABCA1 AGPAT1

5.92e-0458833EFO_0008593
Diseaserostral middle frontal gyrus volume measurement

ADGB ITGB6

6.96e-0414832EFO_0010328
Diseasetriglycerides in medium LDL measurement

TDRD15 BPTF ABCA1

7.20e-0462833EFO_0022322
Diseaseurolithiasis

SHROOM3 DGKD VPS13B

7.55e-0463833MONDO_0024647
DiseaseSitus ambiguus

SHROOM3 DNAH9

8.02e-0415832C0266642
Diseasetriglycerides in small LDL measurement

TDRD15 BPTF ABCA1

8.27e-0465833EFO_0022323
Diseaseextrahepatic cholestasis (biomarker_via_orthology)

ABCA1 NR1H4

1.03e-0317832DOID:13619 (biomarker_via_orthology)
Diseaseosteoarthritis, knee

BRD2 PTPRN2 PITPNB LTBP1

1.05e-03158834EFO_0004616
DiseaseColorectal Neoplasms

ABCA1 NR4A2 NTNG1 GRIN2A LY96

1.12e-03277835C0009404
DiseaseMood Disorders

HTR4 GRIN2A PFKFB3 ADCY3

1.31e-03168834C0525045
Diseaseneutrophil percentage of leukocytes

HTR4 MARK4 AKAP11 BRD3 HORMAD1 CXCR1 CXCR2

1.67e-03610837EFO_0007990
Diseaseneutrophil count

PAPPA2 ADSL HTR4 ZNF423 MARK4 FGB AKAP11 BRD3 CXCR1 CXCR2 LAPTM5

1.67e-0313828311EFO_0004833
DiseaseSjogren's syndrome (is_marker_for)

BST2 MUC5AC

2.07e-0324832DOID:12894 (is_marker_for)
Diseaseopen-angle glaucoma

FNDC3B ABCA1 DGKD ALCAM

2.10e-03191834EFO_0004190
Diseaseprimary biliary cholangitis (is_marker_for)

ABCA1 NR1H4

2.25e-0325832DOID:12236 (is_marker_for)
Diseaseomega-6 polyunsaturated fatty acid measurement

TDRD15 ABCA1 TMEM39A ALCAM

2.35e-03197834EFO_0005680
DiseaseAntiglaucoma preparations and miotics use measurement

FNDC3B ABCA1

2.43e-0326832EFO_0009944
Diseaselevel of Sterol ester (27:1/18:2) in blood serum

TDRD15 MARK4

2.43e-0326832OBA_2045194
Diseasebody fat percentage

FNDC3B BPTF NTNG1 BRD3 ALCAM ADCY3

2.56e-03488836EFO_0007800
Diseasevitamin D measurement

TDRD15 ABCA1 HTR4 UGT1A6 RPP14

2.61e-03336835EFO_0004631

Protein segments in the cluster

PeptideGeneStartEntry
MASTSYDYCRVPMED

BST2

1

Q10589
NTMFTNCYIYNKPTD

BRD3

106

Q15059
TMFTNCYIYNKPGDD

BRD4

131

O60885
VKYCMPTSDKEYSAE

ADGB

891

Q8N7X0
YYNGDPFITKDMVCA

GZMK

186

P49863
FYDNSTTPYCNDLMK

ABCA1

346

O95477
LMYKYPSCESVTDEY

AKAP11

1331

Q9UKA4
AYYIFQEMADKCSPT

COPE

201

O14579
MFSCVKPYEDQNYSA

CAPN5

1

O15484
MTKIFDNCRYYNPSD

BPTF

2996

Q12830
PCYKRVTDMADYTYS

QRICH2

1536

Q9H0J4
MTRLYKYVFCPETTD

RABGEF1

216

Q9UJ41
ISDEYITPMFSFYKS

NR1H4

371

Q96RI1
CQKVPAMDFYRYEVS

PTPRN2

61

Q92932
KLTYDSYSPDTFLEM

MAN2A1

611

Q16706
SSVKPYRVYCDMNTE

FGB

261

P02675
FPSKEAALSVYAAMY

PLPPR5

191

Q32ZL2
DSKNEYSMSTVLEYP

ITGB6

296

P18564
TYYDPVKLQCFDMDE

LTBP1

1456

Q14766
PTFNEMLVYSGYSKE

PIK3C2A

1621

O00443
IKYYAEMCASPDQSD

PGM2L1

576

Q6PCE3
TVYSSNVSPACYEDM

CXCR2

186

P25025
DFMKRISCYEASYQP

PFKFB3

186

Q16875
FSLPEKCDYMDEVTY

HNRNPUL2

596

Q1KMD3
YTCPTEEEYKAMVLQ

GGPS1

136

O95749
AAVKPGTYYSNCMFD

MUC5AC

646

P98088
FTETEKFCLIYPYMR

IRAK3

231

Q9Y616
MYITYVRNCKFTSPG

NOC2L

336

Q9Y3T9
VYSLEGQDCKYTPMF

SMPD4

571

Q9NXE4
YPYCRTIVTNEYMKD

PITPNB

91

P48739
TVEFKCDYSSYMPRV

GPRC6A

126

Q5T6X5
APFTNYMSYTDDNCT

PAPPA2

801

Q9BXP8
QVTMYDYQAMCKPSS

CACNA2D4

931

Q7Z3S7
YAMYNSVKGSCSEPV

FNDC3B

356

Q53EP0
DYSPCMLETETLNKY

CXCR1

26

P25024
KYVDICFPEQMAYSR

C6orf50

81

Q9HD87
STYCVFMVNKPYAIT

HTR4

181

Q13639
METEGSCLENPKYYN

ADCY3

741

O60266
PLSSLMYTACKQYFE

FAM169A

216

Q9Y6X4
SYRHQDKYCQMPSFE

MS4A14

131

Q96JA4
SISYTYCDKMQYPIS

LY96

31

Q9Y6Y9
GKYRVPFYMSTDCES

MARK4

271

Q96L34
EPETLEYYTEKCVMN

DGKD

751

Q16760
SRPYVCTYEDCKMSY

KLF18

961

A0A0U1RQI7
MYSKEEEYVAFSEPC

DNAH9

1656

Q9NYC9
VCLTMKLFYYDEVTP

HORMAD1

171

Q86X24
TYAFLTMTPDINKYS

CCDC168

1756

Q8NDH2
TMSPEASEYETCYVT

CSTF1

91

Q05048
VDLYDTTSNVYCMFT

FAM111B

611

Q6SJ93
PFIKEVCEASSMYYG

LHFPL7

131

Q6ICI0
KADIQMPFTCSVTYY

ALCAM

211

Q13740
PGQSMIKYLEEDFCY

OTOGL

2126

Q3ZCN5
TSMKESTNCPYYNEY

OTOF

286

Q9HC10
APKSQEDTICTMFYY

PTPN13

1696

Q12923
RCMKFVPNETYFSFD

PGBD3

256

Q8N328
STFMDNYSTGYDVKP

NR4A2

61

P43354
SSNYELKPSCVYQMQ

NR4A3

66

Q92570
DYMACQPESTDMTKY

NTNG1

46

Q9Y2I2
MNPTIHKFLYTAEYC

TDO2

381

P48775
YFPKSVSEYSMLNSE

TDRD15

671

B5MCY1
LCSSYMEVPTYLNFK

LAPTM5

151

Q13571
RYPSSNMLKTYFSDV

PROX1

596

Q92786
YASPEMCFVFSDRYK

ADSL

21

P30566
DKEAVSMLVNCPAYY

SHROOM3

1736

Q8TF72
EFSTVLMEVQSKYYC

MSH4

261

O15457
ANEAVCYMPESKYAV

IARS2

306

Q9NSE4
NTMFTNCYIYNKPTD

BRD2

146

P25440
KPDEKAIMTYVSCFY

ACTN3

246

Q08043
KACYEAYRTPTMQEC

ZFHX2

2081

Q9C0A1
SSSPTCMAFQKAYYN

THAP9

626

Q9H5L6
VPIVMSSYQDFYCKK

AGPAT1

206

Q99943
FLPLCFVKSTQYYDM

TMEM39A

301

Q9NV64
CETMKDTPYDYKADI

STK10

206

O94804
MNPKQKCSTLYDYFS

TTC3

1101

P53804
KIFYLSPEGMTSCQY

SLFN12

496

Q8IYM2
FKLTEMQVESSYYSP

VPS13B

401

Q7Z7G8
TKDQYPYLKSVCEMA

PLIN2

36

Q99541
TQSFMEVYSCPYCTN

ZNF423

556

Q2M1K9
YIPRCYTKFSDHMTF

UGT1A6

191

P19224
PSEYHYMKVCLEFQD

RPP14

16

O95059
PNMRTYYFCTDTGKE

PLEKHA5

241

Q9HAU0
AEAPDLYTYFTMLKA

THRSP

51

Q92748
ESVVFIYSMPGYKCS

TWF2

251

Q6IBS0
SYIPEAKASCYGQME

GRIN2A

311

Q12879
SMNYCETPKYQLDTQ

NEB

646

P20929